pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA
Kura Oncology
Kura Oncology clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
- Founded
- 2014
- Employees
- 313
- Programs
- 25
- Drugs
- 14
- Patents
- 132
Kura Oncology projects
13 ClinicalTrials.gov programs sponsored by Kura Oncology.
Kura Oncology has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Darlifarnib
Kura Oncology
Solid Tumors With HRAS Alterations
1 trial -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
1 trial -
KO-947
Kura Oncology
Advanced Malignant Neoplasm
1 trial -
KO-MEN-008
Kura Oncology
Relapsed and/or refractory Acute Myeloid Leukemia
1 trial -
Tipifarnib
Kura Oncology
Advanced Solid Tumor
1 trial -
Tipifarnib
Kura Oncology
NSCLC
1 trial -
Venetoclax
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
Relapsed/Refractory KMT2A-r Acute Leukemia
1 trial -
Ziftomenib
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
AML
1 trial -
Ziftomenib
Kura Oncology
KMT2A-rearranged
1 trial -
Ziftomenib
Kura Oncology
Refractory Acute Leukemia
1 trial -
ziftomenib
Kura Oncology
Gastrointestinal Stromal Tumor (GIST)
1 trial
Frequently asked questions
How many clinical projects does Kura Oncology have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.